Literature DB >> 19900222

Multidrug-resistant and extensively drug-resistant tuberculosis: The new face of an old disease.

Laurie Anne Ferguson1, Jacqueline Rhoads.   

Abstract

PURPOSE: To provide an overview of tuberculosis (TB), especially the persistent threat of multidrug-resistant (MDR) and extensively drug-resistant (XDR), and the role of the nurse practitioner (NP) in diagnosis, treatment, and public health surveillance. DATA SOURCES: Public health sources such as the World Health Organization and the Centers for Disease Control as well as current literature.
CONCLUSIONS: One hundred twenty-five years after the discovery of Mycobacterium tuberculosis, the disease remains a persistent threat and a leading cause of death worldwide. Medication adherence and prevention are critical to successfully treating and ultimately eradicating this killer disease. Healthcare providers need to be knowledgeable in the detection and diagnosis of TB and to understand that they assume responsibility for public health by monitoring treatment adherence and/or appropriate referral. IMPLICATIONS FOR PRACTICE: The persistent and increasing threat of MDR-TB and XDR-TB is a significant public health threat. Healthcare providers need to be knowledgeable and vigilant in diagnosing and treating this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900222     DOI: 10.1111/j.1745-7599.2009.00458.x

Source DB:  PubMed          Journal:  J Am Acad Nurse Pract        ISSN: 1041-2972


  2 in total

1.  Population Pharmacokinetics and Pharmacodynamics of Isoniazid and its Metabolite Acetylisoniazid in Chinese Population.

Authors:  Bing Chen; Hao-Qiang Shi; Meihua Rose Feng; Xi-Han Wang; Xiao-Mei Cao; Wei-Min Cai
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

2.  New strain multidrug resistant tuberculosis G24767 in Puerto Rico: Old disease a continuous threat.

Authors:  Hiram José Maldonado; Michael Cruz; Joel Nieves; Kelvin Rivera; Ricardo Fernández; Miguel Colón; Francisco Fernández
Journal:  Respir Med Case Rep       Date:  2016-08-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.